13 Aug

Moving forward, together

After 102 days, New Zealand has recorded its first new cases of community transmission of Covid-19. As of midday on Wednesday 12th Aug, there are only four cases confirmed, all of which are in Auckland. The New Zealand Government is again using a ‘hard and fast’ approach, and has now set Auckland at alert level 3, while the rest of the country is at alert level 2. This will be reassessed on Friday, August 14th. 

Australian restrictions remain the same, with only Victoria in civil lockdown. 

Key information for clinical trials in Australia and New Zealand: 

• Clinical trials are classed as an essential service in both Australia and New Zealand
• Sites in Australia and New Zealand have telemedicine, virtual, and remote capabilities
• Hospitals and Healthcare continues to operate 
• PSL staff are all set up to work from home; we have prepared for this scenario
• PSL will implement immediately remote monitoring stand operating procedures to ensure study continuity and compliance
• Essential site visits will be conducted considering site, patient and PSL staff safety

As we all are aware, Covid-19 is a tricky virus to contain. Pharmaceutical Solutions has prepared well in advance for this scenario and we continue to operate ‘business as usual’. From today, we are working from home to ensure quality outcomes for our clients. 

As a team, we are in start-up mode with new studies and further, we are confident in our local sites’ virtual and remote capabilities as required. 

As clinical research professionals, caring for people is at the core of all that we do. Now, we need to keep moving, keep our spirits high, and look after one another.

Other News

How Biotechs can utilise Australia and New Zealand to extend seasonal clinical trials and rescue studies

Randomised, controlled trials are considered the gold standard in assessing the safety and effectiveness of potential new medicines and therapies.

Read more
The Effect of the Pandemic on locations for conducting clinical trials for Biotechs

Through the spring of 2020, it became evident that the Covid-19 pandemic would have a dual impact on the clinical research sector. While it has provided the opportunity to conduct research for vaccines, treatments, and diagnostic tests for COVID-19; it has also acted as a major disruptive force, halting trials in their tracks, and exacerbating existing fragilities within the sector.

Read more
Global Clinical Trials take advantage of significant Australian R&D tax incentives

Australia and New Zealand are well-established regions for international clinical trials.  Global sponsors understand the region’s ability to deliver quality research outcomes; rapid start-up, recruitment and participant retention, streamlined ethics and regulatory pathways, internationally accepted quality data from world-leading research facilities and Investigators. 

Read more